Fructose and irritable bowel syndrome

2020 ◽  
Vol 33 (2) ◽  
pp. 235-243 ◽  
Author(s):  
Chloé Melchior ◽  
Véronique Douard ◽  
Moïse Coëffier ◽  
Guillaume Gourcerol
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Breath Test ◽  
Recurrent Abdominal Pain ◽  
Fructose Malabsorption ◽  
Chronic Disorder ◽  
Gi Symptoms ◽  
Irritable Bowel ◽  
Osmotic Load

AbstractIrritable bowel syndrome (IBS) is a chronic disorder characterised by recurrent abdominal pain or discomfort and transit disturbances with heterogeneous pathophysiological mechanisms. The link between food and gastrointestinal (GI) symptoms is often reported by patients with IBS and the role of fructose has recently been highlighted. Fructose malabsorption can easily be assessed by hydrogen and/or methane breath test in response to 25 g fructose; and its prevalence is about 22 % in patients with IBS. The mechanism of fructose-related symptoms is incompletely understood. Osmotic load, fermentation and visceral hypersensitivity are likely to participate in GI symptoms in the IBS population and may be triggered or worsened by fructose. A low-fructose diet could be integrated in the overall treatment strategy, but its role and implication in the improvement of IBS symptoms should be evaluated. In the present review, we discuss fructose malabsorption in adult patients with IBS and the interest of a low-fructose diet in order to underline the important role of fructose in IBS.

scholarly journals FRUCTOSE MALABSORPTION IN CHILDREN WITH FUNCTIONAL DIGESTIVE DISORDERS

2013 ◽  
Vol 50 (3) ◽  
pp. 226-230 ◽  
Author(s):  
Adriana Chebar LOZINSKY ◽  
Cristiane BOE ◽  
Ricardo PALMERO ◽  
Ulysses FAGUNDES-NETO
Keyword(s):  
Aqueous Solution ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Breath Test ◽  
Gastrointestinal Symptoms ◽  
Functional Abdominal Pain ◽  
Hydrogen Breath Test ◽  
Fasting Level ◽  
Fructose Malabsorption ◽  
Irritable Bowel

Context Fructose is a monosaccharide frequently present in natural and artificial juice fruits. When the concentration of fructose in certain food is present in excess of glucose concentration some individuals may develop fructose malabsorption. Objectives To report the frequency of fructose malabsorption utilizing the hydrogen breath test in children with gastrointestinal and/or nutritional disorders. Methods Between July 2011 and July 2012, 43 patients with gastrointestinal and/or nutritional disorders, from both sexes, were consecutively studied, utilizing the hydrogen breath test with loads of the following carbohydrates: lactose, glucose, fructose and lactulose. Fructose was offered in a 10% aqueous solution in the dose of 1 g/kg body weight. Samples were collected fasting and at every 15 minutes after the intake of the aqueous solution for a 2 hour period. Malabsorption was considered when there was an increase of >20 ppm of hydrogen over the fasting level, and intolerance was diagnosed if gastrointestinal symptoms would appear. Results The age of the patients varied from 3 months to 16 years, 24 were boys. The following diagnosis were established: irritable bowel syndrome with diarrhea in 16, functional abdominal pain in 8, short stature in 10, lactose intolerance in 3, celiac disease in 1, food allergy in 1 and giardiasis in 1 patient. Fructose malabsorption was characterized in 13 (30.2%) patients, and intolerance in 1 (2.3%) patient. The most frequent fructose malabsorption was characterized in 7 (16.3%) patients with irritable bowel syndrome and in 4 (9.3%) patients with functional abdominal pain. Conclusions Patients with irritable bowel syndrome and functional abdominal pain were the main cause of fructose malabsorption.

Irritable Bowel Syndrome with Constipation

2015 ◽  
Author(s):  
Loni Tang ◽  
Brooks D. Cash
Keyword(s):  
Irritable Bowel Syndrome ◽  
Differential Diagnosis ◽  
Abdominal Pain ◽  
Digital Rectal Examination ◽  
Recurrent Abdominal Pain ◽  
Differential Diagnoses ◽  
Rectal Examination ◽  
Stool Form ◽  
Alarm Features ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is characterized by recurrent abdominal pain or discomfort that has occurred at least 3 days per month in the 3 months prior to diagnosis. One of the subtypes of this disorder is IBS with constipation (IBS-C), where individuals experience hard or lumpy stools at least 25% of the time and loose or watery stools less than 25% of the time with defecation. This review addresses IBS-C, detailing the epidemiology, etiology, pathophysiology and pathogenesis, diagnosis, differential diagnosis, treatment, and prognosis. A figure shows the Bristol stool form scale. Tables list IBS subtypes, components of digital rectal examination, differential diagnoses for IBS and IBS-C, alarm features, and the American College of Gastroenterology Recommendations. This review contains 1 highly rendered figure, 6 tables, and 71 references. 

Irritable bowel syndrome

2020 ◽  
pp. 2951-2959
Author(s):  
Adam D. Farmer ◽  
Qasim Aziz
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Recurrent Abdominal Pain ◽  
Bowel Habit ◽  
Western World ◽  
Older Individuals ◽  
Butyl Bromide ◽  
Rome Iii ◽  
Fermentable Carbohydrates ◽  
Irritable Bowel

Symptoms suggestive of disturbed lower gastrointestinal function without adequate explanation are very common in adults in the Western world, up to 15% of whom experience such symptoms at any one time, although most do not seek medical advice. The currently used terms are best viewed as an attempt to provide some clinically useful, rather than pathophysiologically accurate, categorization of patients and their symptoms based on disordered gut–brain interactions. Irritable bowel syndrome is defined according to the Rome III criteria as recurrent abdominal pain or discomfort associated with a change in bowel habit for at least 6 months, with symptoms experienced on at least 3 days of at least 3 months. Many subtypes are recognized. Routine haematological and biochemical screening is usually performed on the assumption that it will be normal. Features that raise the suspicion of organic disease and indicate a need for further investigation include the onset of symptoms in middle-aged or older individuals, weight loss, or blood in the stool. Management remains empirical: no single pharmacological agent or group of agents has ever been found to be consistently effective. The principal task of the physician is to provide explanation and reassurance (sometimes supplemented by psychological treatments), but particular symptoms are often treated as follows: (1) constipation—defecation may be eased by supplementary dietary fibre and poorly absorbed fermentable carbohydrates which increase faecal bulk and soften the stool; osmotic laxatives and enemas are used for the severely constipated patient, as well as more novel agents; (2) diarrhoea—attention to diet is often helpful, as are simple antidiarrhoeal agents; and (3) abdominal pain—antispasmodics (e.g. hyoscine butyl bromide) are frequently used, as are antidepressants.

Recurrent Abdominal Pain in Children: Forerunner to Adult Irritable Bowel Syndrome?

2003 ◽  
Vol 8 (3) ◽  
pp. 81-89 ◽  
Author(s):  
Monica Jarrett ◽  
Margaret Heitkemper ◽  
Danita I. Czyzewski ◽  
Robert Shulman
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Recurrent Abdominal Pain ◽  
Irritable Bowel

scholarly journals Irritable bowel syndrome and biliary tract pathology. Clinical analysis

2020 ◽  
pp. 28-38
Author(s):  
T. E. Polunina
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Gastrointestinal Tract ◽  
Biliary Tract ◽  
Emotional Health ◽  
Biological Marker ◽  
Recurrent Abdominal Pain ◽  
Clinical Analysis ◽  
Functional Disorders ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) – a recurrent functional disorder of the gastrointestinal tract (GIT), the main symptom of which is abdominal pain necessarily associated with a change in intestinal function. IBS is a functional intestinal disorder in which recurrent abdominal pain is associated with a defecation act and a change in the frequency or shape of the stool. The diagnosis of IBS remains exclusively clinical. The difficulty in studying IBS, especially from the perspective of its epidemiology, is that there is still no universal and specific biological marker. Very often patients complain about symptoms typical for several functional disorders, in particular, biliary tract pathology and IBS. The article discusses the multi-component causes and mechanisms of IBS formation, which are also present in other functional gastrointestinal tract diseases. Patients with IBS often have functional disorders of the biliary tract (FDBT) that are not associated with organic pathology. There are no reliable differences in the frequency and nature of FDBT in patients with IBS, depending on its current variant - with constipation or diarrhea prevalence. As a result, the treatment of patients with IBS remains a challenge, and the recurrence of the disease depends on the state of psycho-emotional health, the presence of overlap syndrome in most cases. The article presents the main international criteria for diagnostics of IBS. The main approaches to the treatment of IBS are considered. Good results in the treatment of IBS are observed when using drugs that affect the complex of pathophysiological mechanisms of the disease. This is confirmed in the article by a clinical case study. The prescription of the Sparex drug for pain relief in a patient with IBS and FDBT is justified by the fact that it not only eliminates pain, but also improves the rheological properties of bile, typical for overlap “IBS-FDBT” syndrome.

The Clinical Course of Irritable Bowel Syndrome in Young Patients with Neurocirculatory Dystonia

2016 ◽  
pp. 104-105
Author(s):  
Olena Suprun
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Clinical Course ◽  
Family Doctor ◽  
Young Patients ◽  
Pain Syndrome ◽  
Comorbid Conditions ◽  
The Family ◽  
Irritable Bowel

The clinical picture of the combined course of irritable bowel syndrome (IBS) and neurocirculatory dystonia (NCD) in young patients has been described in the article. Features of abdominal pain syndrome and disorders of defecation, depending on the type of NCD (hypertonic or hypotonic) were shown. The conditions under which the exacerbation of IBS occurred in these patients were reviewed. The role of the family doctor in monitoring of the comorbid conditions was shown.

scholarly journals The role of abuse in the development of irritable bowel syndrome: a comparative study

2003 ◽  
Vol 8 (4) ◽  
pp. 88-98
Author(s):  
G Eileen Rossouw ◽  
Anita D Stuart ◽  
H Gertie Pretorius
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Comparative Study ◽  
Full Text ◽  
Bowel Habit ◽  
Functional Bowel Disorder ◽  
Irritable Bowel ◽  
Bowel Disorder

Irritable Bowel Syndrome (IBS) is defined as a chronic relapsing functional bowel disorder of unknown causes which is characterised by attacks of abdominal pain and change of bowel habit resulting in diarrhoea or constipation or both. Opsomming Prikkelbare Dermsindroom (PDS) word gedefinieer as ’n chroniese, herhalende, funksionele ingewandsversteuring wat gekenmerk word deur aanvalle van buikpyn en ‘n verandering in ingewandsgewoontes, wat diarree of hardlywigheid, of beide, tot gevolg het. *Please note: This is a reduced version of the abstract. Please refer to PDF for full text.

Adequate Relief as an Endpoint in Clinical Trials in Irritable Bowel Syndrome

1998 ◽  
Vol 26 (2) ◽  
pp. 76-81 ◽  
Author(s):  
AW Mangel ◽  
BA Hahn ◽  
AT Heath ◽  
AR Northcutt ◽  
S Kong ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Bowel Function ◽  
Recurrent Abdominal Pain ◽  
Response To Therapy ◽  
Multiple Parameters ◽  
Severity Scores ◽  
Irritable Bowel

Irritable bowel syndrome is characterized by recurrent abdominal pain and altered bowel function. In designing studies to evaluate new treatments for this disease, however, it is difficult to select appropriate endpoints to reflect improvement in the range of symptoms of the syndrome. In the present study we evaluated the parameter of adequate relief of abdominal pain and discomfort, as perceived by the patients, as a key endpoint for efficacy in the treatment of patients with irritable bowel syndrome. Abdominal pain and bowel function data were collected daily from 370 patients with the disease during treatment with placebo or a novel potent 5HT3 receptor antagonist. Once every 7 days adequate relief of pain and discomfort was assessed. Quality-of-life data were collected using self-administered questionnaires. The endpoint of adequate relief was significantly ( P < 0.05) correlated with improvement in pain severity scores, percentage of pain-free days, percentage of days with urgency, improvement in stool frequency and consistency, and quality-of-life parameters. Adequate relief of pain and discomfort is significantly correlated with changes in multiple parameters associated with irritable bowel syndrome and can be used as an endpoint for assessing response to therapy in these patients.

Sign in / Sign up

Export Citation Format

Share Document